The 2016 Annual Meeting of American Society of Gene and Cell Therapy (ASGCT) took place on May 4-7, 2016, in Washington. The meeting featured ground breaking clinical trial results, cutting edge technology advancements, and social networking events.
Several SCIDNET partners attended and presented at the conference including:
- SCIDNET Coordinator Prof Bobby Gaspar – Chair of Education session on Orphan Diseases
- Prof Fulvio Mavilio – Lecture entitled “De-risking Gene Therapy for Rare Diseases: The Role of Non-profit Research Organizations”
- Dr Karin Pike – Lecture entitled “Hematologic & Immunologic Diseases I”
- Ian Johnston, PhD – Chair of Tools and Technology Forum during Poster Session II
- Prof Axel Schambach, participated in International Committee and on the Retroviral Vectors Abstract Review Board
- Dr Emmanuelle Six, lecture entitled “Generation of functional regulatory T cells by FOXP3 gene transfer into CD4 T cell from IPEX patients”
The American Society of Gene & Cell Therapy is the primary professional membership organization for gene and cell therapy. The Society’s members are scientists, physicians, patient advocates, and other professionals. The mission of the ASGCT is to advance knowledge, awareness, and education leading to the discovery and clinical application of genetic and cellular therapies to alleviate human disease.
For the consortium, ASGCT was a great opportunity to engage with industry professionals and patients about an exciting and fast-developing area of clinical research and disseminate the SCIDNET project.
